GLP-1 Weight Loss Drugs in 2026: Which Options Work Best for Men With High BMI

Tirzepatide and semaglutide are the two strongest options for men with high BMI right now — and the data gap between them and older agents like liraglutide is wide enough that the choice is rarely close. What actually separates the two frontrunners is how much weight you need to lose, your cardiovascular history, and whether you can stay on the drug long enough to matter.

Semaglutide vs. Tirzepatide: What the Trial Data Actually Show

In the STEP-1 trial, published in NEJM, semaglutide 2.4 mg weekly — sold as Wegovy — produced mean weight loss of 14.9% at 68 weeks versus 2.4% for placebo [10][11]. That's roughly 15 kg for a 100 kg man. Tirzepatide pushes further: in SURMOUNT-1, also published in NEJM, the 15 mg dose hit 22.5% mean weight loss at 72 weeks, with 96% of participants losing at least 5% of body weight [9]. For a man starting at 130 kg with a BMI above 40, that difference — roughly 8–10 additional kilograms — is clinically meaningful, not a rounding error.

The cardiovascular case for semaglutide is currently stronger on hard outcomes. The SELECT trial (NEJM, 2023) enrolled 17,604 people with overweight or obesity and established cardiovascular disease but no diabetes; semaglutide reduced major adverse cardiovascular events by 20% versus placebo [12]. No equivalent cardiovascular outcomes trial has reported yet for tirzepatide as Zepbound. For men with prior MI or known coronary disease, that SELECT data shifts the calculus toward semaglutide even if tirzepatide's weight-loss ceiling is higher.

If you're working through the semaglutide-versus-tirzepatide decision in detail, see our breakdown at semaglutide vs. tirzepatide: key differences men should know before choosing.

Liraglutide, Oral Options, and What's Coming

Saxenda (liraglutide 3.0 mg daily) delivers roughly 4–5% mean weight loss across trials — better than nothing, but far below what semaglutide and tirzepatide produce [2]. It's a daily injection, which some men find preferable to weekly dosing, but the efficacy gap makes it a fallback rather than a first choice. The American Society of Bariatric Physicians guidelines now treat it as a second-line agent when newer options are accessible.

Oral semaglutide (Rybelsus) at standard doses was developed for type 2 diabetes management, not obesity — its weight-loss effect at the 14 mg dose trails the injectable Wegovy formulation. The OASIS-4 trial (Lancet, 2023) tested a 50 mg oral formulation with more competitive results, but that dose isn't yet standard clinical practice. For men who are needle-averse, it's worth discussing with a prescriber, but injectable weekly dosing remains more reliably effective at current approved doses.

The most compelling emerging data comes from retatrutide — a triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 data published in NEJM showed approximately 24% weight loss at 48 weeks at higher doses [7], and REDEFINE-1 Phase 3 data is anticipated to read out in 2026–2027. For men with BMI above 45 who haven't hit their target with tirzepatide, retatrutide represents a plausible next step — but it isn't approved yet. For a deeper look at where the pipeline goes beyond these agents, read beyond GLP-1: which peptides are actually changing men's lives in 2026.

Telehealth providers have expanded access substantially. Platforms like Hims now offer supervised GLP-1 prescribing without requiring in-person visits, which removes a common friction point for men who avoid primary care. You can also compare weight-loss providers side by side before committing to a program. For a full overview of medically supervised options, see our weight management treatment hub.

The practical ceiling on all of this: real-world discontinuation rates exceed 50% within 12 months [17][18]. The drug that "works best" is the one a patient actually stays on — which means gastrointestinal side effect tolerance, cost (typically $900–$1,400/month without coverage), and injection convenience all factor into the correct answer.

Frequently asked questions

Which GLP-1 drug produces the most weight loss for obese men?

Tirzepatide (Zepbound) produces the highest mean weight loss among currently approved GLP-1-class drugs, averaging 22.5% of body weight at the 15 mg dose in SURMOUNT-1. Semaglutide (Wegovy) averages roughly 15% in comparable trials. For men with BMI above 40 who need large absolute fat-mass reductions, tirzepatide is the stronger first-line choice unless cardiovascular history points toward semaglutide's SELECT-trial benefit.

Can men access these drugs through telehealth without seeing a doctor in person?

Yes — multiple telehealth platforms now prescribe semaglutide and tirzepatide remotely after an intake questionnaire and asynchronous clinician review. Providers like [Hims](/go/